Galapagos Announces Collaboration with AstraZeneca

Galapagos NV has announced that its service division BioFocus DPI has entered a new drug discovery collaboration with AstraZeneca. 
 
This collaboration marks the first time AstraZeneca has selected BioFocus DPI to provide drug discovery services. 

Under the terms of the agreement, BioFocus DPI will perform hit-to-lead medicinal chemistry services for AstraZeneca's respiratory and inflammatory drug discovery programs. Total contract value for Galapagos is €650,000.
 
"We are very pleased with this initial contract to support AstraZeneca in developing novel drugs," said Onno van de Stolpe, Chief Executive Officer of Galapagos. 

"Our world class medicinal chemistry expertise within BioFocus DPI will be of great use in this new collaboration and establish the basis for a potentially long term relationship."
 
"We look forward to complementing our hit-to-lead programs with the medicinal chemistry expertise of BioFocus DPI," said Dr. Lars-Erik Arvidsson, Vice President R&D Lund, AstraZeneca.

"We chose to work with BioFocus DPI because of their reputation and ability in modern lead generation methodologies. The ingenuity of their scientists will bring great value to the project."

"We are very positive about our new collaboration, and through this agreement we expect to deliver promising leads for candidate drugs."